講演・口頭発表等 - 田中　一

41. Tanaka Hajime. Prognostic impact of pathological renal parenchymal infiltration in non-metastatic clear cell renal cell carcinoma. AUA Annual Meeting 2022

42. Tanaka Hajime. Renal parenchymal infiltration is the primary determinant of prognosis of patients with non-metastatic clear cell renal cell carcinoma. 37th Annual EAU Congress 2022

43. Tanaka Hajime. Disparities in Cancer-Specific Mortality between Asian and Caucasian Patients with Non-metastatic Renal Cell Carcinoma: Analysis of the INMARC registry. 37th Annual EAU Congress 2022

44. 上原 翔, 松岡 陽, 山本 くらら, 戸出 真宏, 内田 裕將, 福田 翔平, 福島 啓司, 安田 庸輔, 田中 一, 吉田 宗一郎, 横山 みなと, 大橋 健一, 藤井 靖久. 前立腺の篩状癌と腺管内癌の検出におけるMRI標的生検の有用性(Usefulness of MRI-targeted biopsy in detecting cribriform carcinoma and intraductal carcinoma of the prostate). 日本泌尿器科学会総会 2021.12.01

45. 山口 良友, 田中 一, 福島 啓司, 戸出 真宏, 内田 裕將, 福田 翔平, 安田 庸輔, 上原 翔, 吉田 宗一郎, 横山 みなと, 松岡 陽, 藤井 靖久. 原発性腎腫瘍の放射線学的浸潤性特徴が転移性腎細胞癌の予後へ及ぼす影響(Prognostic impact of radiologic infiltrative feature of primary renal tumor in metastatic renal cell carcinoma). 日本泌尿器科学会総会 2021.12.01

46. 田中 一, 島田 航, 布川 裕規, 木村 浩一朗, 山本 浩平, 福田 翔平, 上原 翔, 吉田 宗一郎, 横山 みなと, 松岡 陽, 立石 宇貴秀, 藤井 靖久. 局所進行腎細胞癌における正常腎実質浸潤の意義　画像および組織学的所見に基づく考察. 日本癌治療学会学術集会抄録集 2021.10.01

47. 田中　一. Significance of Radiologic Infiltrative Feature of Primary Renal Tumor in Predicting Patient Survival in Metastatic Renal Cell Carcinoma. AUA Annual Meeting 2021.09.10 web

48. Tanaka Hajime. Prognostic significance of radiologic infiltrative feature of primary renal tumor in metastatic renal cell carcinoma. 36th Annual EAU Congress 2021.07.10 web

49. 福島啓司、木島敏樹、吉田宗一郎、横山みなと、石岡淳一郎、松岡陽、斎藤一隆、松原伸晃、湯浅健、増田均、米瀬淳二、影山幸雄、藤井靖久. 進行尿路上皮癌症例におけるペムブロリズマブの治療効果及び予後：化学放射線療法の治療歴との関連. 第108回 日本泌尿器科学会総会 2020.12.24

50. Uehara Sho, Matsuoka Yoh, Tanaka Hiroshi, Fukuda Shohei, Fukushima Hiroshi, Moriyama Shingo, Tanaka Hajime, Kijima Toshiki, Yoshida Soichiro, Yokoyama Minato, Ishioka Junichiro, Saito Kazutaka, Fujii Yasuhisa. 標的外のsystematic biopsy coreは前立腺がんの有意な検出に対して限定的な意義しかない　MRI多平面再構築を用いた分析(Systematic biopsy cores apart from targets are of limited value for significant prostate cancer detection: Analysis using MRI multiplanar reconstruction). 日本泌尿器科学会総会 2020.12.01

51. Kijima Toshiki, Tanaka Hajime, Yoshida Soichiro, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Saito Kazutaka, Masuda Hitoshi, Matsubara Nobuaki, Yuasa Takeshi, Yonese Junji, Kageyama Yukio, Fujii Yasuhisa. 進行性尿路上皮がん患者における免疫関連有害事象とpembrolizumabの有効性の関連性(Association between immune-related adverse events and efficacy of pembrolizumab in advanced urothelial cancer patients). 日本泌尿器科学会総会 2020.12.01

52. Tanaka Hajime, Shimada Wataru, Fukuda Shohei, Fukushima Hiroshi, Uehara Sho, Moriyama Shingo, Kijima Toshiki, Yoshida Soichiro, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Saito Kazutaka, Fujii Yasuhisa. 臨床的に限局性の腎細胞癌の腫瘍学的転帰の予測における腫瘍不定形性形状の意義(Significance of tumor shape irregularity in predicting oncologic outcomes of clinically localized renal cell carcinoma). 日本泌尿器科学会総会 2020.12.01

53. Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Fukuda S, Fukushima H, Moriyama S, Tanaka H, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y. Who benefits from extra-target sampling in addition to intra-target sampling for the detection of adverse prostate pathology?: Stereological analysis of biopsy-proven cancer sites. The 35th Annual Congress of the European Association of Urology 2020.07.17 Amsterdam Netherlands.

54. Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Fukuda S, Fukushima H, Moriyama S, Tanaka H, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y. Who needs extra-target sampling in addition to intra-target sampling for the detection of adverse prostate pathology?: Spatial analysis of biopsy-proven cancer sites. The 115th annual meeting of the American Urological Association 2020.05.15 Washington DC, USA

55. Matsuoka Y, Ishioka J, Tanaka H, Fukuda S, Fukushima H, Moriyama S, Uehara S, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Saito K, Fujii Y. Apparent diffusion coefficient ratio as a quantitative imaging marker: Utility in a nomogram for predicting biochemical recurrence after radical prostatectomy. The 115th annual meeting of the American Urological Association 2020.05.15 Washington DC, USA

56. Toide M, Tanaka H, Uchida Y, Fukuda S, Fukushima H, Moriyama S, Uehara S, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Stepwise algorithm using CT and MRI for differential diagnosis of fat-poor angiomyolipoma in small renal masses: Prospective validation study. 114th annual meeting of the American Urological Association, 2020 2020 Washington DC, USA

57. Moriyama S, Yokoyama M, Nakamura Y, Fukuda S, Fukushima H, Uehara S, Tanaka H, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Impact of nocturia on deteriorated renal function after adrenalectomy in patients with primary aldosteronism. 114th annual meeting of the American Urological Association, 2020 2020 Washington DC, USA

58. Nakamura Y, Yokoyama M, Yoshida S, Tanaka H, Kijima T, Ishioka J, Matsuoka Y, Saito K, Minami I, Yoshimoto T, Naito S, Ogawa Y, Yamada T, Uchida S, Fujii Y. Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing’s syndrome. The 35th Annual European Association of Urology Congress Virtual, July 2020 2020

59. Tanaka H, Shimada W, Fukuda S, Fukushima H, Moriyama S, Uehara S, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Campbell SC, Fujii Y. Significance of tumor shape irregularity for predicting potential oncologic risks in clinically localized renal cell carcinoma. The 114th Annual Meeting of the American Urological Association, 2020 (Virtual) 2020

60. Tanaka H, Shimada W, Fukuda S, Fukushima H, Moriyama S, Uehara S, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Campbell SC, Fujii Y. Novel classification model of tumour shape irregularity: significance for predicting potential oncologic risks in clinically localised renal cell carcinoma. The 35th Annual Congress of the European Association of Urology, 2020 (Virtual) 2020